Safety and efficacy of human lactoferrin hLF1-11 for the treatment of infectious complications among haematopoietic stem cell transplant recipients part A: clinical study protocol SC12: safety of a single dose of 5 mg of hLF1-11 given to autologous haematopoietic stem cell transplant recipients.

Trial Profile

Safety and efficacy of human lactoferrin hLF1-11 for the treatment of infectious complications among haematopoietic stem cell transplant recipients part A: clinical study protocol SC12: safety of a single dose of 5 mg of hLF1-11 given to autologous haematopoietic stem cell transplant recipients.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Lactoferrin 1-11 (Primary)
  • Indications Bacterial infections; Mycoses
  • Focus Adverse reactions
  • Sponsors AM-Pharma
  • Most Recent Events

    • 24 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top